Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently head of diagnostics at the Swiss group. Schwan (pictured above ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

Keep up with the latest news in business & general aviation and specific featured experts on Wednesday’s AirMail Focus It is our mission to be the go-to leaders in the aviation industry. GlobalAir.com ...

View Popular mobile phones under Rs. 6,000 in India. Checkout Popular 4G phones under Rs. 6,000 from different mobile brands.